CN108239073A - 化合物、医药组成物及其用途 - Google Patents
化合物、医药组成物及其用途 Download PDFInfo
- Publication number
- CN108239073A CN108239073A CN201711394855.7A CN201711394855A CN108239073A CN 108239073 A CN108239073 A CN 108239073A CN 201711394855 A CN201711394855 A CN 201711394855A CN 108239073 A CN108239073 A CN 108239073A
- Authority
- CN
- China
- Prior art keywords
- compound
- substituted
- unsubstituted
- alkyl
- cycloalkyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 0 CC=CC=CCI(OC(C=CC*(NC)=C)=CC)=C Chemical compound CC=CC=CCI(OC(C=CC*(NC)=C)=CC)=C 0.000 description 5
- VJUDVVHGQMPPEI-ZCFIWIBFSA-N CNC[C@@H]1OCCC1 Chemical compound CNC[C@@H]1OCCC1 VJUDVVHGQMPPEI-ZCFIWIBFSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
- C07D307/34—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D307/38—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D307/52—Radicals substituted by nitrogen atoms not forming part of a nitro radical
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D307/78—Benzo [b] furans; Hydrogenated benzo [b] furans
- C07D307/82—Benzo [b] furans; Hydrogenated benzo [b] furans with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the hetero ring
- C07D307/84—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
- C07D307/85—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
- C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
- C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
- C07D333/06—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to the ring carbon atoms
- C07D333/14—Radicals substituted by singly bound hetero atoms other than halogen
- C07D333/20—Radicals substituted by singly bound hetero atoms other than halogen by nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
Claims (22)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201662438707P | 2016-12-23 | 2016-12-23 | |
USUS62/438,707 | 2016-12-23 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN108239073A true CN108239073A (zh) | 2018-07-03 |
Family
ID=62700298
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201711394855.7A Pending CN108239073A (zh) | 2016-12-23 | 2017-12-21 | 化合物、医药组成物及其用途 |
Country Status (2)
Country | Link |
---|---|
CN (1) | CN108239073A (zh) |
TW (1) | TW201823222A (zh) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2020110009A1 (en) * | 2018-11-27 | 2020-06-04 | Novartis Ag | Cyclic tetramer compounds as proprotein convertase subtilisin/kexin type 9 (pcsk9) inhibitors for the treatment of metabolic disorders |
WO2021143762A1 (en) * | 2020-01-17 | 2021-07-22 | Shengke Pharmaceuticals (Jiangsu) Ltd. | Novel compounds as inhibitors of pcsk9 |
WO2023280155A1 (en) * | 2021-07-06 | 2023-01-12 | Shengke Pharmaceuticals (Jiangsu) Ltd. | Novel compounds as inhibitors of pcsk9 |
Citations (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6653087B1 (en) * | 1997-02-07 | 2003-11-25 | The Scripps Research Institute | Convergent synthesis of combinatorial library |
TW201412722A (zh) * | 2012-07-26 | 2014-04-01 | Kowa Co | 用以降低血中ldl之醫藥 |
CN104159895A (zh) * | 2012-03-07 | 2014-11-19 | 卡迪拉保健有限公司 | 用于治疗血脂异常及相关疾病的新化合物 |
CN104487060A (zh) * | 2012-05-25 | 2015-04-01 | 克塔巴西斯制药有限公司 | 使前蛋白转化酶枯草溶菌素/kexin 9型(pcsk9)减少的方法 |
CN105143203A (zh) * | 2013-04-17 | 2015-12-09 | 辉瑞大药厂 | 用于治疗心血管疾病的n-哌啶-3-基苯甲酰胺衍生物 |
CN105228616A (zh) * | 2013-03-15 | 2016-01-06 | 实发生物医学公司 | 抗前蛋白转化酶枯草杆菌蛋白酶Kexin 9型(抗PCSK9)化合物及其用于治疗和/或预防心血管疾病的方法 |
CN105378159A (zh) * | 2013-02-15 | 2016-03-02 | Srx心脏有限责任公司 | 调节血清低密度脂蛋白(LDL)水平的前蛋白转化酶枯草杆菌蛋白酶/Kexin 9 型(PCSK9)变构结合配体 |
CN105473141A (zh) * | 2013-03-15 | 2016-04-06 | 实发生物医学公司 | 治疗和/或预防心血管疾病的抗pcsk9化合物和方法 |
-
2017
- 2017-12-20 TW TW106144843A patent/TW201823222A/zh unknown
- 2017-12-21 CN CN201711394855.7A patent/CN108239073A/zh active Pending
Patent Citations (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6653087B1 (en) * | 1997-02-07 | 2003-11-25 | The Scripps Research Institute | Convergent synthesis of combinatorial library |
CN104159895A (zh) * | 2012-03-07 | 2014-11-19 | 卡迪拉保健有限公司 | 用于治疗血脂异常及相关疾病的新化合物 |
CN104487060A (zh) * | 2012-05-25 | 2015-04-01 | 克塔巴西斯制药有限公司 | 使前蛋白转化酶枯草溶菌素/kexin 9型(pcsk9)减少的方法 |
TW201412722A (zh) * | 2012-07-26 | 2014-04-01 | Kowa Co | 用以降低血中ldl之醫藥 |
CN105378159A (zh) * | 2013-02-15 | 2016-03-02 | Srx心脏有限责任公司 | 调节血清低密度脂蛋白(LDL)水平的前蛋白转化酶枯草杆菌蛋白酶/Kexin 9 型(PCSK9)变构结合配体 |
CN105228616A (zh) * | 2013-03-15 | 2016-01-06 | 实发生物医学公司 | 抗前蛋白转化酶枯草杆菌蛋白酶Kexin 9型(抗PCSK9)化合物及其用于治疗和/或预防心血管疾病的方法 |
CN105473141A (zh) * | 2013-03-15 | 2016-04-06 | 实发生物医学公司 | 治疗和/或预防心血管疾病的抗pcsk9化合物和方法 |
CN105143203A (zh) * | 2013-04-17 | 2015-12-09 | 辉瑞大药厂 | 用于治疗心血管疾病的n-哌啶-3-基苯甲酰胺衍生物 |
Non-Patent Citations (1)
Title |
---|
来源于CAPLUS等数据库: ""STN检索报告"", 《数据库REGISTRY(在线)》 * |
Cited By (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2020110009A1 (en) * | 2018-11-27 | 2020-06-04 | Novartis Ag | Cyclic tetramer compounds as proprotein convertase subtilisin/kexin type 9 (pcsk9) inhibitors for the treatment of metabolic disorders |
US11026993B2 (en) | 2018-11-27 | 2021-06-08 | Novartis Ag | Cyclic tetramer compounds as proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors for the treatment of metabolic disorders |
CN113166114A (zh) * | 2018-11-27 | 2021-07-23 | 诺华股份有限公司 | 作为蛋白质原转换酶枯草杆菌蛋白酶/kexin9型(pcsk9)抑制剂的用于治疗代谢障碍的环状四聚体化合物 |
AU2019387294B2 (en) * | 2018-11-27 | 2022-09-08 | Novartis Ag | Cyclic tetramer compounds as proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors for the treatment of metabolic disorders |
US11813306B2 (en) | 2018-11-27 | 2023-11-14 | Novartis Ag | Cyclic tetramer compounds as proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors for the treatment of metabolic disorders |
WO2021143762A1 (en) * | 2020-01-17 | 2021-07-22 | Shengke Pharmaceuticals (Jiangsu) Ltd. | Novel compounds as inhibitors of pcsk9 |
CN115279736A (zh) * | 2020-01-17 | 2022-11-01 | 晟科药业(江苏)有限公司 | 作为pcsk9抑制剂的新化合物 |
CN115279736B (zh) * | 2020-01-17 | 2024-08-16 | 晟科药业(江苏)有限公司 | 作为pcsk9抑制剂的化合物 |
WO2023280155A1 (en) * | 2021-07-06 | 2023-01-12 | Shengke Pharmaceuticals (Jiangsu) Ltd. | Novel compounds as inhibitors of pcsk9 |
Also Published As
Publication number | Publication date |
---|---|
TW201823222A (zh) | 2018-07-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP6915003B2 (ja) | ヒト血漿カリクレイン阻害剤 | |
RU2351596C2 (ru) | Производные n-[гетероарил(пиперидин-2-ил)метил]бензамида и их применение в терапии | |
CN101619043B (zh) | 喹唑啉衍生物及其医药用途 | |
CN100415720C (zh) | 喹啉衍生物和喹唑啉衍生物以及含有这些化合物的药物组合物 | |
DK2121636T3 (en) | Process for the preparation of piperazinyl and diazepanylbenzamide derivatives | |
Rudolf et al. | Development of human calcitonin gene-related peptide (CGRP) receptor antagonists. 1. Potent and selective small molecule CGRP antagonists. 1-[N 2-[3, 5-dibromo-N-[[4-(3, 4-dihydro-2 (1 H)-oxoquinazolin-3-yl)-1-piperidinyl] carbonyl]-d-tyrosyl]-l-lysyl]-4-(4-pyridinyl) piperazine: the first CGRP antagonist for clinical trials in acute migraine | |
JP7074903B2 (ja) | イミダゾピリダジン化合物 | |
TWI433672B (zh) | 吲唑化合物 | |
CN101346357A (zh) | 氨基二氢噻嗪衍生物 | |
CN102746285A (zh) | 作为hedgehog途径调节剂的化合物和组合物 | |
JP7263266B2 (ja) | ジヒドロ-ピロロ-ピリジン誘導体 | |
JP2007530550A (ja) | 異脂肪血症を治療するための化合物および方法 | |
JP2010522186A (ja) | 化合物 | |
SG191097A1 (en) | 5,6-DIHYDRO-IMIDAZO[1,2-a]PYRAZIN-8-YLAMINE DERIVATIVES USEFUL AS INHIBITORS OF BETA-SECRETASE (BACE) | |
AU2015290007B2 (en) | Fused quinoline compunds as pi3k, mTor inhibitors | |
CN108239073A (zh) | 化合物、医药组成物及其用途 | |
CN102177136A (zh) | 吡咯烷n-苄基衍生物 | |
CN101616894A (zh) | 作为丝氨酸蛋白酶抑制剂的式(ⅰ)化合物 | |
CN109563144A (zh) | 化合物 | |
RU2683022C1 (ru) | Производные гетероциклические алкильные соединения в качестве селективных ингибиторов гистондеацетилазы и содержащие их фармацевтические композиции | |
CN102216279A (zh) | 一类含有嘧啶酮苯基的化合物、其药物组合物及其制备方法和用途 | |
CN107108582A (zh) | β‑分泌酶的2,3,4,5‑四氢吡啶‑6‑胺和3,4‑二氢‑2H‑吡咯‑5‑胺化合物抑制剂 | |
CN100494182C (zh) | 肿瘤坏死α因子信号的调节因子 | |
TW394764B (en) | Oxygen-containing heterocyclic derivatives | |
CN104955826A (zh) | 可用于治疗神经学疾病和病症的螺-喹唑酮衍生物 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
CB03 | Change of inventor or designer information | ||
CB03 | Change of inventor or designer information |
Inventor after: Chen Shian Inventor after: Lin Qiuya Inventor after: Laili Yingxuan Inventor after: Yang Pingxun Inventor after: Huang Zhaoling Inventor after: Liao Baixiang Inventor after: Liu Jiawei Inventor after: Liu Yanxi Inventor after: Lin Hesheng Inventor after: Chen Shanwei Inventor before: Chen Shian Inventor before: Laili Yingxuan Inventor before: Yang Pingxun Inventor before: Huang Zhaoling Inventor before: Liao Baixiang Inventor before: Liu Jiawei Inventor before: Liu Yanxi |
|
WD01 | Invention patent application deemed withdrawn after publication | ||
WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20180703 |